E-cigarette effectiveness in smoking cessation

Nov.21.2022
E-cigarette effectiveness in smoking cessation
A study by the UK Cochrane Group found that nicotine e-cigarettes can improve smoking cessation rates.

Recently, the UK-based Cochrane Collaboration conducted 78 studies involving 22,052 smokers, comparing the use of electronic cigarettes with the following factors:


Nicotine replacement therapy (such as patches or gum);


Varenicline, a medication that helps people quit smoking;


Nicotine-free electronic cigarette;


Other types of electronic cigarettes that contain nicotine (such as pods);


Actions of support, such as advice or consultation.


The research was mostly conducted in the United States (34 studies), United Kingdom (16 studies), and Italy (8 studies).


Key Conclusion


Using nicotine-containing e-cigarettes is more effective than using nicotine replacement therapy or non-nicotine e-cigarettes for quitting smoking. The most common adverse effects of using e-cigarettes with nicotine are throat or oral irritation, headaches, coughing and nausea. As people continue to use nicotine e-cigarettes, these effects become lessened over time.


Research summary


There is strong evidence to suggest that nicotine-containing e-cigarettes are more effective for smoking cessation than NRT, while moderate quality evidence suggests that nicotine-containing e-cigarettes are more effective for smoking cessation than non-nicotine e-cigarettes. Comparing nicotine replacement therapy to standard care or no treatment also shows benefit, but with lower certainty and requiring further research to confirm the effect. In most cases, the confidence intervals for data on AEs, SAEs, and other safety indicators are broad, with no differences observed between nicotine and non-nicotine e-cigarettes in terms of AEs, or between nicotine e-cigarettes and NRT. The overall incidence rate of SAEs was low across all study groups. No evidence was found for serious harm from nicotine e-cigarettes, but the longest follow-up period was two years and the number of studies was limited. The primary limitation of the evidence base continues to be imprecision due to limited numbers of RCTs and typically low event rates, but further RCTs are currently ongoing. To ensure that this review continues to provide up-to-date information for decision-makers, it is a living system review. Searches are conducted monthly and the review is updated when new relevant evidence becomes available. Please refer to the Cochrane Systematic Reviews Database for the current status of this review.


Statement:


This article is based on third-party information that has been edited by machine translation, and is only intended for industry communication and learning purposes.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the truthfulness or accuracy of the article's content. The translation of this article is only for the purpose of industry-related communication and research.


Due to limitations in the translator's abilities, the translated article may not fully express the original content. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government in regards to any domestic, Hong Kong, Macau, Taiwan, or international statements and positions.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us to have it removed.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Alan Zhao: In the Post-“Absolute Resolve” Era: Speculating on U.S.-Referenced Regulatory Alignment and the Restructuring of Order in South America’s Novel Tobacco Market
Alan Zhao: In the Post-“Absolute Resolve” Era: Speculating on U.S.-Referenced Regulatory Alignment and the Restructuring of Order in South America’s Novel Tobacco Market
Alan Zhao analyzes post-Operation Absolute Resolve geopolitics and the rise of “U.S.-referenced regulatory alignment” in South America’s novel tobacco market as U.S. influence grows. Using regulatory reliance, digitalized enforcement, and industrial shifts, he assesses how rule redesign may alter market access, competition, and supply chains, asking how firms can find durable certainty as order is rewritten.
Jan.06 by 2Firsts Perspectives
Mexican Senate Approves Nationwide Ban on E-Cigarettes and Vapes
Mexican Senate Approves Nationwide Ban on E-Cigarettes and Vapes
Mexico’s Senate passed a reform to the General Health Law banning the production, importation, sale, and advertising of e-cigarettes and vape products nationwide. The bill passed with 76 votes in favor, 37 against, and one abstention.
Dec.12 by 2FIRSTS.ai
The Spark of Reason| 2Firsts 2026 New Year Message
The Spark of Reason| 2Firsts 2026 New Year Message
Looking ahead to 2026, we do so with genuine anticipation. This will be a milestone year—the dawn of a new era.
Jan.01
Wisconsin Lawmakers Revive Bill to Raise Legal Age for Tobacco and Vaping Purchases to 21
Wisconsin Lawmakers Revive Bill to Raise Legal Age for Tobacco and Vaping Purchases to 21
Wisconsin Senate Bill 524 (SB 524) has been reintroduced to raise the legal purchasing age for tobacco and electronic nicotine products from 18 to 21, aiming to eliminate the gap between state law and the federal “Tobacco 21” standard. Some retailers in Madison have already voluntarily adopted the 21-year age limit, while the American Lung Association is urging swift legislative action.
Dec.04 by 2FIRSTS.ai
ZYN Rolls Out “X-Low” Campaign in the UK to Target Low-Strength Nicotine Pouch Market
ZYN Rolls Out “X-Low” Campaign in the UK to Target Low-Strength Nicotine Pouch Market
Philip Morris International’s (PMI) nicotine pouch brand ZYN has launched an “X-Low” low-strength campaign in the UK, accelerating its push into the ultra-low nicotine pouch segment, with updated packaging and new flavours already rolled out in both the UK and the Philippines.
Dec.09 by 2FIRSTS.ai
Product | Airis, Kangvape and HAYATI Launch Christmas-Themed E-cigarettes in UK and US Online Markets
Product | Airis, Kangvape and HAYATI Launch Christmas-Themed E-cigarettes in UK and US Online Markets
As the Christmas holiday season approaches in Europe and North America, e-cigarette brands such as Airis, Kangvape and HAYATI have successively launched Christmas special editions featuring festive-themed designs and selected limited-time flavors, which are now available through online channels in both the United States and the United Kingdom.
Dec.15 by 2FIRSTS.ai